Orchid Pharma: NCLT approved Merger Of Dhanuka Lab With Co. Is Expected To Create A Larger Integrated Pharma Company With Potential Revenue Of ₹1,400–1,500 Cr And EBITDA Of ₹200–250 Cr, Driven By Operational Synergies, Cost Savings, And Stronger Market Presence.
Orchid Pharma: NCLT approved Merger Of Dhanuka Lab With Co. Is Expected To Create A Larger Integrated Pharma Company With Potential Revenue Of ₹1,400–1,500 Cr And EBITDA Of ₹200–250 Cr, Driven By Operational Synergies, Cost Savings, And Stronger Market Presence.